<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Biogen Inc — News on 6ix</title>
<link>https://6ix.com/company/biogen-inc</link>
<description>Latest news and press releases for Biogen Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 20 Apr 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/biogen-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354d2e78dffbe2df0e5d56.webp</url>
<title>Biogen Inc</title>
<link>https://6ix.com/company/biogen-inc</link>
</image>
<item>
<title>TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region</title>
<link>https://6ix.com/company/biogen-inc/news/tj-biopharma-enters-into-agreement-with-biogen-for-felzartamab-assets-in-the-greater-china-region</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/tj-biopharma-enters-into-agreement-with-biogen-for-felzartamab-assets-in-the-greater-china-region</guid>
<pubDate>Mon, 20 Apr 2026 11:30:00 GMT</pubDate>
<description>Biogen Inc. (Nasdaq: BIIB) and TJ Biopharma ("TJ Bio") today announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio's exclusive rights to felzartamab in the Greater China Region. With this agreement, Biogen now owns exclusive worldwide rights to felzartamab, which is currently being evaluated in global Phase 3 clinical studies across multiple immune-mediated diseases.</description>
</item>
<item>
<title>Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region</title>
<link>https://6ix.com/company/biogen-inc/news/biogen-enters-into-agreement-with-tj-biopharma-for-felzartamab-assets-in-the-greater-china-region</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/biogen-enters-into-agreement-with-tj-biopharma-for-felzartamab-assets-in-the-greater-china-region</guid>
<pubDate>Mon, 20 Apr 2026 11:30:00 GMT</pubDate>
<description>With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one ownerAdvancing felzartamab – a CD38-directed antibody with potential broad applicability across a range of immune-mediated conditions – in the Greater China Region presents an important opportunity in a key global marketAgreement builds on TJ Biopharma’s development success of felzartamab in China and productive clinical collaboration in Biogen</description>
</item>
<item>
<title>Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology</title>
<link>https://6ix.com/company/biogen-inc/news/biogen-to-acquire-apellis-enhancing-the-companys-growth-portfolio-in-immunology-and-rare-disease-bolstering-growth-outlook-and-accelerating-expansion-into-nephrology-1</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/biogen-to-acquire-apellis-enhancing-the-companys-growth-portfolio-in-immunology-and-rare-disease-bolstering-growth-outlook-and-accelerating-expansion-into-nephrology-1</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare</description>
</item>
<item>
<title>FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy</title>
<link>https://6ix.com/company/biogen-inc/news/fda-approves-new-high-dose-regimen-of-spinrazar-nusinersen-for-spinal-muscular-atrophy</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/fda-approves-new-high-dose-regimen-of-spinrazar-nusinersen-for-spinal-muscular-atrophy</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in</description>
</item>
<item>
<title>Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity</title>
<link>https://6ix.com/company/biogen-inc/news/biogen-announces-second-positive-phase-2-litifilimab-trial-in-cutaneous-lupus-erythematosus-at-2026-american-academy-of-dermatology-annual-meeting-showing-a-significant-reduction-in-skin-disease-activity</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/biogen-announces-second-positive-phase-2-litifilimab-trial-in-cutaneous-lupus-erythematosus-at-2026-american-academy-of-dermatology-annual-meeting-showing-a-significant-reduction-in-skin-disease-activity</guid>
<pubDate>Sat, 28 Mar 2026 04:00:00 GMT</pubDate>
<description>In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with</description>
</item>
<item>
<title>Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics</title>
<link>https://6ix.com/company/biogen-inc/news/alteogen-enters-into-a-license-agreement-with-biogen-for-development-and-commercialization-of-hybrozymetm-based-subcutaneous-biologics</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/alteogen-enters-into-a-license-agreement-with-biogen-for-development-and-commercialization-of-hybrozymetm-based-subcutaneous-biologics</guid>
<pubDate>Wed, 25 Mar 2026 12:00:00 GMT</pubDate>
<description>Alteogen Inc. (KOSDAQ: 196170) announced today that it has entered into an exclusive license agreement with Biogen Inc. for the development and commercialization of subcutaneous (SC) formulations of biologics utilizing ALT-B4 powered by Alteogen's Hybrozyme™ technology.</description>
</item>
<item>
<title>Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting</title>
<link>https://6ix.com/company/biogen-inc/news/biogen-to-present-new-late-breaking-litifilimab-phase-2-amethyst-data-in-cutaneous-lupus-erythematosus-at-2026-american-academy-of-dermatology-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/biogen-to-present-new-late-breaking-litifilimab-phase-2-amethyst-data-in-cutaneous-lupus-erythematosus-at-2026-american-academy-of-dermatology-annual-meeting</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE)Litifilimab was</description>
</item>
<item>
<title>Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy</title>
<link>https://6ix.com/company/biogen-inc/news/biogen-presents-additional-salanersen-data-showing-new-motor-milestones-achieved-in-children-with-sma-previously-treated-with-gene-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/biogen-presents-additional-salanersen-data-showing-new-motor-milestones-achieved-in-children-with-sma-previously-treated-with-gene-therapy</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to</description>
</item>
<item>
<title>Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences</title>
<link>https://6ix.com/company/biogen-inc/news/biogen-to-share-new-sma-data-at-muscular-dystrophy-association-and-sma-europe-conferences-10</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/biogen-to-share-new-sma-data-at-muscular-dystrophy-association-and-sma-europe-conferences-10</guid>
<pubDate>Thu, 05 Mar 2026 12:30:00 GMT</pubDate>
<description>Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)New Phase 1b data further illustrate potential of salanersen in SMA, as Phase 3 studies begin to evaluate this investigational drug that has the potential for high potency with once-yearly dosing CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – will present new data and updates from its spinal muscle atrophy (SMA) research programs, i</description>
</item>
<item>
<title>Biogen Announces Board Chair Transition</title>
<link>https://6ix.com/company/biogen-inc/news/biogen-announces-board-chair-transition</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/biogen-announces-board-chair-transition</guid>
<pubDate>Wed, 11 Feb 2026 05:00:00 GMT</pubDate>
<description>Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair CAMBRIDGE, Mass., Feb. 11, 2026</description>
</item>
<item>
<title>Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China</title>
<link>https://6ix.com/company/biogen-inc/news/biologics-license-application-for-subcutaneous-formulation-of-leqembir-lecanemab-for-the-treatment-of-early-alzheimers-disease-designated-for-priority-review-in-china</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/biologics-license-application-for-subcutaneous-formulation-of-leqembir-lecanemab-for-the-treatment-of-early-alzheimers-disease-designated-for-priority-review-in-china</guid>
<pubDate>Mon, 09 Feb 2026 02:00:00 GMT</pubDate>
<description>TOKYO and CAMBRIDGE, Mass., Feb. 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) for the subcutaneous formulation (subcutaneous autoinjector: SC-AI) of “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), an anti-amyloid beta (Aβ) protofibril antibody, whi</description>
</item>
<item>
<title>Sales of Leqembi® totaled 20.7 billion yen in the fourth quarter 2025</title>
<link>https://6ix.com/company/biogen-inc/news/sales-of-leqembir-totaled-207-billion-yen-in-the-fourth-quarter-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/sales-of-leqembir-totaled-207-billion-yen-in-the-fourth-quarter-2025-1</guid>
<pubDate>Fri, 06 Feb 2026 11:23:00 GMT</pubDate>
<description>BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the fourth quarter 2025, in conjunction with their partner Biogen's fourth quarter report. In total, sales of JPY 20.7 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 127 million, which is an increase of approximately 31 percent compared to the royalty obtained by BioArctic for the fourth quarter 2024.</description>
</item>
<item>
<title>Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy</title>
<link>https://6ix.com/company/biogen-inc/news/nature-medicine-publishes-results-pivotal-123000437</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/nature-medicine-publishes-results-pivotal-123000437</guid>
<pubDate>Wed, 04 Feb 2026 12:30:00 GMT</pubDate>
<description>Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersenThe high-dose regimen of nusinersen also slowed neurodegeneration more rapidly, as measured by neurofilament, than the 12 mg regimen CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that Nature Medicine published results from the Phase 2/3 DEVOTE study evaluating</description>
</item>
<item>
<title>Lupus Research Alliance Applauds U.S. FDA Breakthrough Therapy Designation for Litifilimab in Cutaneous Lupus Erythematosus</title>
<link>https://6ix.com/company/biogen-inc/news/lupus-research-alliance-applauds-u-135000849</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/lupus-research-alliance-applauds-u-135000849</guid>
<pubDate>Wed, 28 Jan 2026 13:50:00 GMT</pubDate>
<description>The Lupus Research Alliance applauds the decision by the U.S. Food and Drug Administration (FDA) to grant Breakthrough Therapy designation for litifilimab (BIIB059) in clinical development by Biogen Inc. for the treatment of cutaneous lupus erythematosus (CLE) – a chronic skin disease for which there are no specifically approved treatments. The FDA grants this designation to expedite the review of drugs that may demonstrate substantial improvement over available therapies.</description>
</item>
<item>
<title>Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options</title>
<link>https://6ix.com/company/biogen-inc/news/biogen-litifilimab-receives-fda-breakthrough-123000526</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/biogen-litifilimab-receives-fda-breakthrough-123000526</guid>
<pubDate>Wed, 28 Jan 2026 12:30:00 GMT</pubDate>
<description>Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activityLitifilimab has the potential to be a first-in-class therapy targeting blood dendritic cell antigen 2 (BDCA2) in CLE, a chronic autoimmune skin disease that has a substantial impact on the daily life of patients, and may result in permanent scarring and disfigurementFDA Breakthrough Therapy Designation is</description>
</item>
<item>
<title>FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under Priority Review</title>
<link>https://6ix.com/company/biogen-inc/news/fda-accepts-leqembir-iqliktm-lecanemab-irmb-supplemental-biologics-license-application-as-a-subcutaneous-starting-dose-for-the-treatment-of-early-alzheimers-disease-under-priority-review-1</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/fda-accepts-leqembir-iqliktm-lecanemab-irmb-supplemental-biologics-license-application-as-a-subcutaneous-starting-dose-for-the-treatment-of-early-alzheimers-disease-under-priority-review-1</guid>
<pubDate>Sun, 25 Jan 2026 23:30:00 GMT</pubDate>
<description>If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA action date set for May 24, 2026 TOKYO and CAMBRIDGE, Mass., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that</description>
</item>
<item>
<title>FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review</title>
<link>https://6ix.com/company/biogen-inc/news/fda-accepts-leqembir-iqliktm-lecanemab-irmb-supplemental-biologics-license-application-as-a-subcutaneous-starting-dose-for-the-treatment-of-early-alzheimers-disease-under-priority-review</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/fda-accepts-leqembir-iqliktm-lecanemab-irmb-supplemental-biologics-license-application-as-a-subcutaneous-starting-dose-for-the-treatment-of-early-alzheimers-disease-under-priority-review</guid>
<pubDate>Sun, 25 Jan 2026 05:00:00 GMT</pubDate>
<description>If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for</description>
</item>
<item>
<title>Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy</title>
<link>https://6ix.com/company/biogen-inc/news/biogen-receives-european-commission-approval-160500808</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/biogen-receives-european-commission-approval-160500808</guid>
<pubDate>Mon, 12 Jan 2026 16:05:00 GMT</pubDate>
<description>Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA1Biogen is dedicated to partnering with the SMA community to advance care through scientific innovation and a commitment to enhancing outcomes for people living with SMA CAMBRIDGE, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the European Commission (EC) has granted ma</description>
</item>
<item>
<title>Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China</title>
<link>https://6ix.com/company/biogen-inc/news/biologics-license-application-for-subcutaneous-formulation-of-leqembir-lecanemab-for-the-treatment-of-early-alzheimers-disease-accepted-in-china</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/biologics-license-application-for-subcutaneous-formulation-of-leqembir-lecanemab-for-the-treatment-of-early-alzheimers-disease-accepted-in-china</guid>
<pubDate>Tue, 06 Jan 2026 01:00:00 GMT</pubDate>
<description>If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the initiation of treatment for this progressive, relentless diseaseTOKYO and CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the Biologics License Application (BLA) f</description>
</item>
<item>
<title>Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada</title>
<link>https://6ix.com/company/biogen-inc/news/biogen-receives-health-canada-authorization-for-zurzuvaetm-zuranolone-the-first-and-only-treatment-indicated-for-adults-with-postpartum-depression-in-canada</link>
<guid isPermaLink="true">https://6ix.com/company/biogen-inc/news/biogen-receives-health-canada-authorization-for-zurzuvaetm-zuranolone-the-first-and-only-treatment-indicated-for-adults-with-postpartum-depression-in-canada</guid>
<pubDate>Tue, 09 Dec 2025 12:00:00 GMT</pubDate>
<description>TORONTO, December 09, 2025--Biogen Canada Inc. today announced that Health Canada has issued a Notice of Compliance (NOC) for ZURZUVAE™ (zuranolone) for the treatment of moderate or severe postpartum depression (PPD) in adults following childbirth. ZURZUVAE is a once-daily, 14-day oral single course treatment for women with PPD. This first-of-its-kind treatment offers relief from depressive symptoms, with benefits seen in clinical studies as early as day 3, significant reduction of symptoms by t</description>
</item>
</channel>
</rss>